Deep Molecular Response Duration Predicts Treatment-Free Remission in Chronic Myeloid Leukemia Rescued After Resistance, Warning, or Major Molecular Response (SOHO 2026) - Sep 1, 2026 - Abstract #CML-310; Location: LEVEL 3, HALL B3; "Therapy at discontinuation was second-generation ATP-competitive TKI, ponatinib, or asciminib in 88%, 8%, and 5% of patients. TKI discontinuation after salvage therapy is feasible and safe in patients achievingDMR4.5. TFR rates seem higher than previously reported, potentially due to longer treatment exposure, as DMR4.5 duration was the main predictor of success. Specific prerequisites for treatment discontinuation may be established in this setting."
Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR
|
|
Delphine Rea MD MD PhD 1; Franck Nicolini MD PhD 2; Gabriel Etienne MD 3; Lydia Roy MD 4; Martine Escoffre-Barbe MD 5; Emilie Cayssials MD PhD 6; Gabrielle Roth-Guepin MD 7; Francois-Xavier Mahon MD PhD 3; Jean-Michel Cayuela PhD 1
|